Membranous nephropathy (MN) is a common cause of adult nephrotic syndrome. Rituximab, a type Ⅰ anti-CD20 monoclonal antibody, is an effective treatment of MN. However, its response rate is merely 60% during a follow-up period of up to 24 months. Obinutuzumab is a type Ⅱ humanized anti-...
Obinutuzumab with Tacrolimus as a Bridge for Membranous Nephropathy Membranous Nephropathy (MN) is a common cause of nephrotic syndrome (NS) in adults. Recognition of MN as an antibody mediated autoimmune disease has enable... H Patel,KD Jhaveri - 《Journal of the American Society of Nephrology》...
ADULTSBackground: Minimal change disease (MCD) is a common cause of adult nephrotic syndrome. Most adults with MCD achieve complete remission (CR) after initial steroid therapy. However, approximately 30% of adults who respond to steroids experience frequent relapses, becoming...
Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. Rituximab, a type I anti-CD20 antibody, has been shown to be an effective therapy in treatment of patients with MN associated with M-type phospholipase A2 receptor (PLA2R) antibodies. Despite its effectiveness up ...
The primary endpoint was treatment response, which was defined as overall remission of nephrotic syndrome with no need for rescue therapy after obinutuzumab versus rituximab treatment. The secondary measures included immunological remission and safety profiles. RESULTS. Among the 51 participants, 20 ...
Obinutuzumab Is Effective and Safe for Membranous Nephropathy with Very High Risk: A Retrospective Study from China Membranous Nephropathy (MN) is a common cause of nephrotic syndrome (NS) in adults. Recognition of MN as an antibody mediated autoimmune disease has enable... D Chen,H Li,Y Tu,...
New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are? Nephrotic proteinuria is the hallmark of several glomerulonephritis determined by different pathogenetic mechanisms, including autoimmune, degenerative and... B Basu,A Angeletti,B Islam,... - 《Frontiers in Immunology》 ...
The primary endpoint was treatment response, which was defined as overall remission of nephrotic syndrome with no need for rescue therapy after obinutuzumab versus rituximab treatment. The secondary measures included immunological remission and safety profiles. RESULTS. Among the 51 participants, 20 ...
Membranous Nephropathy (MN) is a common cause of nephrotic syndrome (NS) in adults. Recognition of MN as an antibody mediated autoimmune disease has enable... N Klomjit,F Fervenza,L Zand - 《Kidney International Reports》 被引量: 0发表: 2020年 Obinutuzumab as Initial or Second-line Therapy...
B cell recoveryChildrenDaratumumabObinutuzumabRelapseRituximabSteroid-dependent nephrotic syndromeBACKGROUND :Steroid-sensitive nephrotic syndrome (SSNS) is, in most patients, a chronic disease with 80% experiencing at least one relapse after first flare. B cell depletion using rituximab is effective in ...